McPherson’s has entered FY27 with first-quarter sales about 11% below the prior corresponding period, after a disappointing FY26 loss and a costly operating transition. The company says EBITDA growth remains achievable, but its transformation now faces a test of execution and leadership change.
- FY26 revenue of $118.3 million and underlying EBITDA of $4.3 million
- Statutory net loss after tax of $20.3 million
- First-quarter FY27 sales approximately 11% below the prior corresponding period
- Net cash fell to $4.5 million after a $5.5 million inventory investment
- CEO Brett Charlton to step down as board searches for a successor
Weak FY27 Start Extends McPherson’s Earnings Challenge
McPherson’s Limited (ASX:MCP) has begun FY27 with sales running approximately 11% below the prior corresponding period, putting fresh pressure on a business that has yet to turn a three-year transformation into stronger shareholder returns.
The comparison is complicated by elevated wholesaler stock orders in the first quarter of FY26, which McPherson’s says were repeated in December 2025 and will also affect the first-half FY27 comparison. Even with that qualification, the trading update leaves the company needing a stronger second half to deliver its stated ambition of underlying EBITDA growth. Management expects the full-year result to be weighted towards 2H27, but did not provide a quantified EBITDA forecast.
FY26 Loss Exposes Cost of Operating Transition
Chairman Ari Mervis described FY26 as “a disappointing result” after continuing-operations revenue reached $118.3 million, underlying EBITDA came in at $4.3 million and McPherson’s recorded a statutory net loss after tax of $20.3 million.
The company said its new pharmacy wholesaler and third-party logistics model delivered approximately $2.8 million of incremental EBITDA benefit and approximately $5.6 million of incremental EBIT benefit during the year. But changes to product ranges, availability problems and execution issues in parts of the pharmacy channel disrupted sales and prevented those operating improvements from translating into the expected financial result. The December 2025 announcement of the new 3PL operating model had positioned the shift as a route to lower fixed costs and greater scalability.
Cash Buffer Preserved Despite Inventory Build
McPherson’s finished FY26 with net cash of $4.5 million, down from $8.8 million a year earlier, while its debt facilities remained undrawn. The main drain was a deliberate $5.5 million investment in inventory to restore availability of core products after periods in which the company could not fully meet customer demand.
The board expects that inventory investment to unwind progressively through FY27 as stock levels normalise, releasing cash back to the balance sheet. It also maintained a measured on-market buy-back, saying it wanted to balance its view that the shares were materially undervalued against the need to preserve financial flexibility. No dividend was declared, reflecting the retained loss position and FY26 performance.
CEO Departure Adds Leadership Test
Chief executive and managing director Brett Charlton is stepping down after more than three years in the role. His departure was already disclosed with a six-month transition period and an immediate search for a successor; the AGM addresses confirmed that this was his final annual meeting as CEO. The board’s priorities now include appointing a leader for the next phase while continuing its own renewal, including a replacement for retiring non-executive director Alison Cook.
Charlton highlighted the scale of the restructuring under his tenure: pharmacy distribution expanded by almost 1,000 outlets to more than 4,500, the product range was reduced from more than 1,200 stock-keeping units to about 600, and employee costs fell from $38.2 million in FY23 to $24.9 million. Selling, general and administrative costs declined from $15.8 million to $12.4 million. Those figures describe a leaner platform, but management’s own assessment is that the benefits will only count if they produce better sales and earnings.
Brands and Execution Become the FY27 Battleground
Swisspers delivered a solid performance and Manicare retained leadership positions in several categories, while Lady Jayne, Dr. LeWinn’s and Fusion Health were more affected by the transition, particularly in pharmacy. McPherson’s has invested in innovation, digital capability, direct-to-consumer platforms and influencer marketing, but acknowledged that those investments should only be judged successful if they translate into stronger commercial results.
The immediate questions are whether product availability and pharmacy ranging can be stabilised, whether the inventory build releases the expected cash, and whether the new CEO can convert the company’s simplified structure into sustained growth. With first-quarter sales down and the recovery weighted to the second half, the margin for further execution slippage appears limited.
Bottom Line?
McPherson’s has completed much of the restructuring, but weak first-quarter sales mean FY27 must show that lower costs and improved availability can finally become revenue and EBITDA growth.
Questions in the middle?
- Can McPherson’s convert its new pharmacy and logistics model into sales growth after the first-quarter decline?
- How quickly will the $5.5 million inventory investment unwind and strengthen cash generation?
- Will the incoming CEO change the execution priorities or strategy for Lady Jayne, Dr. LeWinn’s and Fusion Health?